

Prof. Dr. med. Georg Lenz, MD

Current Position: Director of Department of Internal Medicine A, University Hospital Münster
Contact: Department of Internal Medicine A
Hematology, Haemostaseology, Oncology and Pneumology,
Albert-Schweitzer-Campus 1, Building A1
48149 Münster, Germany
Ph: +49 251 83 47587, Fax: +49 251 83 47588
E-mail: georg.lenz@ukmuenster.de

EDUCATION

1994-2001 School of Medicine at the Universität Erlangen-Nürnberg and at the Freie Universität of Berlin.

PROFESSIONAL EXPERIENCE:

2002-2005 Assistant physician at the Department of Internal Medicine III Hematology/Oncology at the Klinikum Grosshadern at the Ludwig-Maximilians Universität, Munich.

2005-2009 Postdoctoral research fellow in the Laboratory of Dr. Louis Staudt at the Lymphoid Malignancies Section, Metabolism Branch at the National Cancer Institute, Bethesda, USA.

2009-2014 Principal investigator at the Department of Hematology, Oncology and Tumor Immunology at the Charité – Universitätsmedizin Berlin.

2009 Appointment as Assistant professor on the “Molecular Pathogenesis of malignant Lymphomas” at the Charité – Universitätsmedizin Berlin.

2012-2013 Senior physician in the Department of Hematology, Oncology and Tumor Immunology at the Charité – Universitätsmedizin Berlin.

2013-2014 Senior leading physician in the Department of Hematology, Oncology and Tumor Immunology at the Charité – Universitätsmedizin Berlin.

2014-2017 W3 Professorship and Head of the “Translational Oncology Unit”, University Hospital Münster.

Since 2017 Director of Department of Internal Medicine A, University Hospital Münster.

AWARDS

08/2008 Technology Transfer Award of the National Cancer Institute

10/2009 World Health Summit & Pfizer Award

10/2013 Artur-Pappenheim Award of the German Society of Hematology and Oncology

11/2013 Together with Daniel Krappmann and colleagues: Paula und Richard von Hertwig-Preis für interdisziplinäre Zusammenarbeit, Helmholtz Zentrum Munich

11/2013 Monika Kutzner Award for Cancer Research

SELECTED PUBLICATIONS:

1. Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, **Lenz G**. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. *Blood*. 2017 Jul 20; 130 (3): 310-322.
2. Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, **Lenz G**. B-cell receptor-driven MALT1

- activity regulates MYC signaling in mantle cell lymphoma. *Blood*. 2017 Jan 19; 129 (3): 333-346.
3. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, **Lenz G**. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. *Leukemia* 2015 Jul; 29 (7): 1578-86.
 4. Weilemann A., Grau M., Erdmann T., Merkel O., Sobhiafshar U., Anagnostopoulos I., Hummel M., Siegert A., Hayford C., Madle H., Wollert-Wulf B., Fichtner I., Dörken B., Dirnhofer S., Mathas S., Janz M., Emre NC., Rosenwald A., Ott G., Lenz P., Tzankov A., **Lenz G**. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. *Blood*. 2015 Jan 1; 125 (1): 124-32.
 5. Rahal R., Frick M., Romero R., Korn JM., Kridel R., Chunchan F., Meissner B., Bhang H., Ruddy D., Kauffmann A., Farsidjani A., Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S., Dietze K., Dörken B., Steidl C., Tzankov A., Hummel M., Monahan J., Morrissey M., Fritsch C., Sellers WR., Cooke VG., Gascoyne RD., **Lenz G***, Stegmeier F*. Pharmacological and genomic profiling identifies NFκB-targeted treatment strategies for mantle cell lymphoma. *Nature Medicine*. 2014 Jan; 20 (1): 87-92. ***Equally contributing last and corresponding author.**
 6. Nogai H., Wenzel SS., Hailfinger S., Grau M., Kaergel E., Seitz V., Wollert-Wulf B., Pfeifer M., Wolf A., Frick M., Dietze K., Madle H., Tzankov A., Hummel M., Dörken B., Scheidereit C., Janz M., Lenz P., Thome M., **Lenz G**. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. *Blood*. 2013 Sep 26; 122 (13): 2242-50.
 7. Pfeifer M., Grau M., Lenze D., Wenzel SS., Wolf A., Wollert-Wulf B., Dietze K., Nogai H., Storek B., Madle H., Dörken B., Janz M., Dirnhofer S., Lenz P., Hummel M., Tzankov A., **Lenz G**. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. *PNAS*. 2013 Jul 23; 110 (30): 12420-5.
 8. Davis RE*, Ngo VN*, **Lenz G***, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*. 2010 Jan 7; 463 (7277): 88-92. ***Equally contributing first author.**
 9. **Lenz G**, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal gene signatures in large-B-cell lymphomas. *N Engl J Med*. 2008 Nov 27; 359 (22): 2313-23.
 10. **Lenz G***, Davis RE*, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science*. 2008 Mar 21; 319 (5870): 1676-9. ***Equally contributing first author.**